NOMASKERS.ORG

WHO recommends against using remdesivir on hospitalised Covid patients 'because there's no proof it works'


Fraud, Scams & Kickbacks 0 Comments 11/20/2020 

(but recommends wearing masks, with no proof they work)

- November 20, 2020

 Doctors should not treat coronavirus patients with remdesivir 'regardless of how ill they are', the World Health Organization (WHO) has warned.

The antiviral showed early promise in pre-clinical Covid-19 trials and has been used around the world to treat people with severe disease, including in the UK.

But officials at the WHO have now said there is 'no evidence' it boosts people's chances of surviving the disease or stops them falling ill enough to need mechanical ventilation.

Scientists at the global health body are officially recommending against its use after reviewing evidence from four international trials of over 7,000 patients. 

They have warned there is the 'possibility of important harm' when using the experimental Ebola drug - it can sometimes cause kidney and liver damage in some patients.  

The WHO Guideline Development Group (GDG) described the drug as an expensive 'gamble' - a five-day course of treatment for one patient costs around £1,773 ($2,340). 

For comparison, the steroid dexamethasone costs just £5 ($6.60) per patient and has been scientifically proven to improve survival in the most ill Covid patients.

Writing in the British Medical Journal, they said: 'Paying a high price for remdesivir without good evidence of mortality benefits a gamble.'

However, the WHO admits the certainty of evidence from the studies is low and has encouraged more studies to dig into the drug's benefit. 

Doctors should not treat coronavirus patients with remdesivir 'regardless of how ill they are', the World Health Organization (WHO) has warned

Doctors should not treat coronavirus patients with remdesivir 'regardless of how ill they are', the World Health Organization (WHO) has warned 

Remdesivir, sold under the brand name Veklury, was developed by California-based Gilead Sciences to treat Ebola, the deadly hemorrhagic fever that emerged in West Africa in 2014.

It works by blocking an enzyme that helps the coronavirus make copies of itself and, in turn, spread throughout the body. 

 

In cell and animal models, studies showed the drug blocked the activity of Severe Acute Respiratory Syndrome (SARS) and MERS (Middle East Respiratory Syndrome), which are cousins of Covid-19. The early results raised hopes it could be effective on the new virus. 

There have been claims of miraculous recovery, improved survival odds and shorter illness, but other studies have found it makes no difference to patients in hospital with Covid-19. 

Remdesivir is given intravenously in a five-day treatment course using six vials of the medication. 

The WHO's recommendation is part of a living guideline to help doctors make better decisions with their patients.

Living guidelines are useful in fast moving research areas like Covid-19 because they allow researchers to update previously vetted and peer-reviewed evidence summaries as new information becomes available.

Remdesivir has received worldwide attention as a potentially effective treatment for severe Covid-19 and is increasingly used to treat patients in hospital. But its role in clinical practice has remained uncertain.

Today’s recommendation is based on a new evidence review comparing the effects of several drug treatments for Covid-19. 

It includes data from four international randomised trials involving over 7,000 patients hospitalised for Covid-19.

After reviewing the evidence, the WHO GDG expert panel concluded that remdesivir has no meaningful effect on mortality or on other important outcomes for patients, such as the need for mechanical ventilation or time to clinical improvement.

The panel acknowledged that the certainty of evidence is low and said the evidence did not prove that remdesivir has no benefit.

Rather, they said there is no evidence based on currently available data that it does improve important patient outcomes.

But given 'the remaining possibility of important harm', as well as the relatively high cost and resource implications associated with remdesivir, it must be given intravenously, they judged this to be an appropriate recommendation.

They also support continued enrolment into trials evaluating remdesivir, especially to provide higher certainty of evidence for specific groups of patients. 

In May, after two studies showed remdesivir could shorten hospital stays, the Medicines and Healthcare products Regulatory Agency and Food and Drug Administration (FDA) authorised the drug to be used in emergencies on patients in Britain and the US.  

It was also one of among a cocktail of drugs used to treat President Donald Trump when he contracted the virus earlier this month. 


   - November 19, 2020A team of Irish medical and public health professionals recently published a White Paper entitled “COVID-19 Alternative Strategy: A Case for Health and Socioeconomic Wellbeing,” calling for an “evidence-based” approach to pandemic management. In the paper, the team provides a cost-benefit analysis of lockdowns and scrutinizes their overall efficacy while ...  READ MORE
- Fielden Nolan (nolanf),  11/19/2020 
   - September 18, 2020AbstractBackground:Observational evidence suggests that mask wearing mitigates transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is uncertain if this observed association arises through protection of uninfected wearers (protective effect), via reduced transmission from infected mask wearers (source control), or both.Objective:To assess whether rec...  READ MORE
- Fielden Nolan (nolanf),  11/18/2020 
   Abstract There is no biological history of mass masking until the current era. It is important to consider possible outcomes of this society-wide experiment. The consequences to the health of individuals is as yet unknown. Masked individuals have measurably higher inspiratory flow than non-masked individuals. This study is of new masks removed from manufacturer packaging, as well as a laundered cl...  READ MORE
- Fielden Nolan (nolanf),  11/17/2020 
   Download the PDF attachment below....  READ MORE
- Fielden Nolan (nolanf),  11/14/2020 
   Download the PDF attachment by clicking Download below....  READ MORE
- Fielden Nolan (nolanf),  11/14/2020 
   Download the PDF by clicking the attachment link below....  READ MORE
- Fielden Nolan (nolanf),  11/14/2020 
   LInk: https://www.cdc.gov/coronavirus/2019-ncov/global-covid-19/shielding-approach-humanitarian.htmlSee Jon Rappoport's view on this document: https://blog.nomorefakenews.com/2020/11/02/cdc-plans-covid-concentration-camps/This document presents considerations from the perspective of the U.S. Centers for Disease Control & Prevention (CDC) for implementing the shielding approach in...  READ MORE
- Fielden Nolan (nolanf),  11/02/2020 
  

Association of American Physicians and Surgeons

Definitive study establishes conclusively not only that masks don't work, but WHY.
Category: Published Studies: Masks are INEFFECTIVE
curated by Marilyn M. Singleton, M.D., J.D. – http://marilynsingletonmdjd.com/Updated September 26, 2020IntroductionCOVID-19 is as politically-charged as it is infectious. Early in the COVID-19 pandemic, the WHO, the CDC and NIH’s Dr. Anthony Fauci discouraged wearing masks as not useful for non-health care workers. Now they recommend wearing cloth face coverings in public setting...  READ MORE
- Fielden Nolan (nolanf),  10/18/2020 
   - October 06, 2020[Open the link above to to view the charts which reveal there is no correlation (or "clear science") behind the use of masks and rates of "infection".] Excerpt:In case it isn’t obvious, these charts fail to show any correlation between mask mandates (which presumably increase the wearing of masks) and reductions in COVID-19 infections. If you l...  READ MORE
- Fielden Nolan (nolanf),  10/07/2020 
   From: https://www.gpadacenter.org/faqs-ada-small-business-and-face-mask-policies- July 10, 2020The ADA and Small Business: Frequently Asked Questions About Face Mask Policies and Serving Customers with Disabilities.The Great Plains ADA Center has received many questions regarding face mask policies and the ADA from the business community. We have collected a summary of these questions and our...  READ MORE
- Fielden Nolan (nolanf),  10/02/2020 

VIEW News Item

NY: COVID checkpoints are back: Cops will be out 'in force'

Questions Thanksgiving travelers from out of state
VIEW News Item

FL: Anthony Sabatini files 8 lawsuits over mandatory mask mandates

"It’s overkill, and it’s not the role of government."
VIEW News Item

UK: Thousands of COVID-19 deaths 'will be wiped off the official toll'

Counted victims if they died from any cause months later after beating disease
VIEW News Item

Model Bella Hadid gives the NYPD the middle finger

Calls out police officers for not wearing masks
VIEW News Item

THE CULT OF THE BRAVE NEW NORMAL

Subjects are becoming "becoming alienated from themselves"
VIEW News Item

PCR tests: How they “work” and what you aren’t being told.

"Scientists and doctors starting lawsuits around the world"

VIEW Blog Item

A Message to Maskers

Do you believe nomaskers are a threat? If so, read on...

We appreciate your donations to NOMASKERS.ORG, because without them this site would not be possible. You do not need a PayPal account in order to donate with your credit card. Just click on the Donate button below. You will be prompted for the amount you wish to contribute.